US Insurer United Rewards Amgen’s Early Entry With Bevacizumab And Trastuzumab
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.
You may also be interested in...
By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.
Pfizer has cleared the way to launching its Zirabev bevacizumab biosimilar in the US on 31 December this year following a patent-litigation settlement with Roche.
Removing legal hurdles and putting biosimilars on preferred formulary tiers will increase access and cut the cost of biologic therapies in the US, argues the chief of major healthcare distributor AmerisourceBergen.